【Hocance Biotech】Announcement of the Company's Q1 2026 Consolidated Financial Report Submitted to the Board of Directors
Key facts
- 【Hocance Biotech】Announcement of the Company's Q1 2026 Consolidated Financial Report Submitted to the Board of Directors
- Hocance Biotech submitted its Q1 2026 consolidated financial report to the board. For the period from January 1 to March 31, 2026, operating revenue was NT$190,868 thousand, net profit attributable to parent company owners was NT$52,793 thousand, and basic EPS was NT$0.59.
- Source: PR Times
- Date: April 28, 2026
Direct answer
Hocance Biotech submitted its Q1 2026 consolidated financial report to the board. For the period from January 1 to March 31, 2026, operating revenue was NT$190,868 thousand, net profit attributable to parent company owners was NT$52,793 thousand, and basic EPS was NT$0.59.
- Citation
- 【Hocance Biotech】Announcement of the Company's Q1 2026 Consolidated Financial Report Submitted to the Board of Directors (April 28, 2026), PR Times
- Source
- PR Times
- Date
- April 28, 2026
Hocance Biotech submitted its Q1 2026 consolidated financial report to the board. For the period from January 1 to March 31, 2026, operating revenue was NT$190,868 thousand, net profit attributable to parent company owners was NT$52,793 thousand, and basic EPS was NT$0.59.
📋 Article Processing Timeline
- 📰 Published: April 28, 2026 at 09:00
- 🔍 Collected: April 29, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 29, 2026 at 08:27 (27 min after Collected)
2. Date of approval by the Audit Committee: 2026/04/28
3. Reporting period of financial statements or annual self-declared financial information: 2026/01/01~2026/03/31
4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NTD): 190,868
5. Cumulative operating gross profit (gross loss) from January 1 to the end of this period (in thousands of NTD): 134,561
6. Cumulative operating profit (loss) from January 1 to the end of this period (in thousands of NTD): 58,409
7. Cumulative pre-tax net profit (net loss) from January 1 to the end of this period (in thousands of NTD): 68,648
8. Cumulative net profit (net loss) for this period from January 1 to the end of this period (in thousands of NTD): 52,793
9. Cumulative net profit (loss) attributable to owners of the parent company from January 1 to the end of this period (in thousands of NTD): 52,793
10. Cumulative basic earnings per share (loss) from January 1 to the end of this period (in NTD): 0.59
11. Total assets at the end of the period (in thousands of NTD): 1,990,823
12. Total liabilities at the end of the period (in thousands of NTD): 364,273
13. Equity attributable to owners of the parent company at the end of the period (in thousands of NTD): 1,626,550
14. Other matters that should be specified: None
FAQ
What are the key facts in this article?
Hocance Biotech submitted its Q1 2026 consolidated financial report to the board. For the period from January 1 to March 31, 2026, operating revenue was NT$190,868 thousand, net profit attributable to parent company owners was NT$52,793 thousand, and basic EPS was NT$0.59.
What is the direct answer?
Hocance Biotech submitted its Q1 2026 consolidated financial report to the board. For the period from January 1 to March 31, 2026, operating revenue was NT$190,868 thousand, net profit attributable to parent company owners was NT$52,793 thousand, and basic EPS was NT$0.59.
What is the source and date?
PR Times: https://mops.twse.com.tw/material/twse-1783-2026-04-28-1ec21e48 | April 28, 2026